DK1067905T3 - Bruseformuleringer - Google Patents

Bruseformuleringer

Info

Publication number
DK1067905T3
DK1067905T3 DK99923373T DK99923373T DK1067905T3 DK 1067905 T3 DK1067905 T3 DK 1067905T3 DK 99923373 T DK99923373 T DK 99923373T DK 99923373 T DK99923373 T DK 99923373T DK 1067905 T3 DK1067905 T3 DK 1067905T3
Authority
DK
Denmark
Prior art keywords
shower formulations
shower
formulations
Prior art date
Application number
DK99923373T
Other languages
Danish (da)
English (en)
Inventor
Wolfram Tritthart
Gottfried Koelbl
Mario Andre Piskernig
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Application granted granted Critical
Publication of DK1067905T3 publication Critical patent/DK1067905T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99923373T 1998-03-31 1999-03-20 Bruseformuleringer DK1067905T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen
PCT/DE1999/000798 WO1999049842A1 (de) 1998-03-31 1999-03-20 Brauseformulierungen

Publications (1)

Publication Number Publication Date
DK1067905T3 true DK1067905T3 (da) 2003-02-03

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99923373T DK1067905T3 (da) 1998-03-31 1999-03-20 Bruseformuleringer

Country Status (29)

Country Link
US (1) US6242002B1 (bg)
EP (1) EP1067905B1 (bg)
JP (1) JP4469494B2 (bg)
KR (1) KR100607395B1 (bg)
CN (1) CN1138529C (bg)
AR (1) AR018829A1 (bg)
AT (1) ATE224703T1 (bg)
AU (1) AU753194B2 (bg)
BG (1) BG65043B1 (bg)
BR (1) BR9909266A (bg)
CA (1) CA2326502C (bg)
CZ (1) CZ300705B6 (bg)
DE (2) DE19814257A1 (bg)
DK (1) DK1067905T3 (bg)
ES (1) ES2183555T3 (bg)
HK (1) HK1036010A1 (bg)
HU (1) HU229793B1 (bg)
IL (1) IL138605A (bg)
NO (1) NO329143B1 (bg)
NZ (1) NZ506989A (bg)
PL (1) PL192049B1 (bg)
PT (1) PT1067905E (bg)
RU (1) RU2221554C2 (bg)
SK (1) SK284477B6 (bg)
TR (1) TR200002812T2 (bg)
TW (1) TW580398B (bg)
UA (1) UA66847C2 (bg)
WO (1) WO1999049842A1 (bg)
ZA (1) ZA200005133B (bg)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
IL151888A0 (en) * 2000-03-28 2003-04-10 Biochemie Gmbh Granulated particles with masked taste
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
MXPA06007453A (es) * 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
JP2007517054A (ja) * 2003-12-31 2007-06-28 シーマ・ラブス、インコーポレイテッド 概して線状の発泡性経口フェンタニル投薬形態および投与方法
US7033511B2 (en) 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP3449928A1 (en) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
RU2011119494A (ru) * 2008-10-14 2012-11-27 Макнейл Аб Многокомпонентная интраоральная лекарственная форма препарата и ее применение
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2014009247A (es) 2012-02-01 2014-10-14 Intercontinental Great Brands Llc Tableta para bebida baja en calorias.
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
WO2021239541A1 (en) * 2020-05-28 2021-12-02 Unilever Ip Holdings B.V. Tablet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
ES2074769T3 (es) 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
EP0592484B1 (de) 1991-07-01 1995-01-18 Gergely, Gerhard, Dr. Reaktionsdotierte brausesysteme
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
AU672617B2 (en) 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
CA2153243A1 (en) * 1993-01-27 1994-08-18 Harold E. Selick Compositions and methods for transdermal drug delivery
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
DE59400446D1 (de) * 1993-04-15 1996-08-29 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen Wirkstoff, und Verfahren zur Herstellung
DK0813865T3 (da) 1993-04-20 2001-11-19 Hexal Ag Plaster med virksomt stof
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
AU677432B2 (en) 1993-09-09 1997-04-24 Gerhard Gergely Effervescent granulated material and method for its preparation
CN1082828C (zh) 1993-11-12 2002-04-17 杰哈德·盖尔盖伊 制备粒状材料的方法
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau, Reinhard, 37242 Bad Sooden-Allendorf Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
EP0866691B2 (en) 1995-11-06 2005-01-26 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
PT1067905E (pt) 2003-02-28
NZ506989A (en) 2002-09-27
HK1036010A1 (en) 2001-12-21
ATE224703T1 (de) 2002-10-15
RU2221554C2 (ru) 2004-01-20
HUP0101427A2 (hu) 2001-08-28
HU229793B1 (en) 2014-07-28
DE59902843D1 (de) 2002-10-31
BG104841A (bg) 2001-07-31
CA2326502A1 (en) 1999-10-07
WO1999049842A1 (de) 1999-10-07
SK14322000A3 (sk) 2001-07-10
UA66847C2 (uk) 2004-06-15
JP4469494B2 (ja) 2010-05-26
CZ20003482A3 (en) 2001-05-16
CA2326502C (en) 2008-08-05
US6242002B1 (en) 2001-06-05
NO329143B1 (no) 2010-08-30
BG65043B1 (bg) 2007-01-31
ES2183555T3 (es) 2003-03-16
PL343260A1 (en) 2001-07-30
PL192049B1 (pl) 2006-08-31
IL138605A0 (en) 2001-10-31
NO20004721D0 (no) 2000-09-21
BR9909266A (pt) 2000-11-21
SK284477B6 (sk) 2005-04-01
IL138605A (en) 2005-11-20
CZ300705B6 (cs) 2009-07-22
TW580398B (en) 2004-03-21
AR018829A1 (es) 2001-12-12
HUP0101427A3 (en) 2001-12-28
AU4029499A (en) 1999-10-18
CN1138529C (zh) 2004-02-18
ZA200005133B (en) 2001-02-28
KR100607395B1 (ko) 2006-08-02
JP2002509872A (ja) 2002-04-02
EP1067905A1 (de) 2001-01-17
AU753194B2 (en) 2002-10-10
TR200002812T2 (tr) 2001-01-22
EP1067905B1 (de) 2002-09-25
DE19814257A1 (de) 1999-10-07
CN1295463A (zh) 2001-05-16
NO20004721L (no) 2000-09-21
KR20010042317A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
DK1067905T3 (da) Bruseformuleringer
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
IS2325B (is) Örgerðar samsetningar epleróns
PT1130966E (pt) Formulacoes antiparasitarias
DE69918109D1 (de) Haarwaschmittel
DE69900634T2 (de) Shampoozusammensetzungen
ID29635A (id) Formulasi mikrokapsul
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ID27655A (id) Formulasi mikrokapsul
ATE275676T1 (de) Duschkombination
DE69928004D1 (de) Badewanne
ATE217021T1 (de) Präparationsmittel
DK1077684T3 (da) Brusepræparater
DE59910104D1 (de) Hausgeräteschrank
DE59702693D1 (de) Handbrause
CA93752S (fr) Baignoire
DE59912020D1 (de) Duschgel
DE59800220D1 (de) Duschkabine
ATA32198A (de) Beschlag
ATA128198A (de) Dusche
ITMI20000412A0 (it) Doccia
NO980820L (no) Dusjhode